Acurx Pharmaceuticals announced a new media series to update investors on its lead antibiotic candidate, ibezapolstat (IBZ), which targets drug-resistant Clostridioides difficile infection (CDI). The

Acurx Pharmaceuticals has initiated the PATHFINDER clinical trial for its antibiotic Ibezapolstat, aimed at patients suffering from recurrent C. difficile infections.

Reported Tuesday, Sep 29 - 8:15am EDT (TheFly subscription required to read more.)

Acurx Pharmaceuticals showcased the promising in vitro efficacy of their new antibiotic, Ibezapolstat, against C. difficile at a major symposium, highlighting its potential benefits over existing treatments.

Acurx Pharmaceuticals has received FDA conditional acceptance and USPTO trademark allowance for its leading antibiotic candidate, Ibezapolstat, which marks significant progress in its commercialization journey.

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the...

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3...

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15), FiscalAI reports. Here are the key takeaways from Acurx Pharmaceuticals’ conference call: FDA guidance supports a potential approval pathway for ibezapolstat through the planned single [...]

Acurx reported $10.7 million in cash, a $2.3 million Q2 loss and higher R&D spending as ibezapolstat development advanced.

Acurx Pharmaceuticals, Inc. reports significant advancements in developing new antibiotics and provides its financial performance for Q2 2026.

Acurx Pharmaceuticals secures new patents in Japan and Mexico for its innovative antibiotic class, further enhancing its position in the biopharmaceutical industry.

Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program.According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior work included high-resolution elucidation of the interaction of ibezapolstat with its...

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior work included high-resolution elucidation of the interaction of ibezapolstat with its molecular target, DNA polymerase IIIC, with mechanistic findings...

Acurx Pharmaceuticals has received FDA guidance for its Ibezapolstat program, paving the way for a streamlined Phase 3 trial aimed at treating C. difficile infections.

Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support...

Acurx Pharmaceuticals presented data highlighting the microbiome preservation potential of Ibezapolstat in treating multiply-recurrent C. difficile infections.

Reported Tuesday, Jul 14 - 8:08am EDT (TheFly subscription required to read more.)

Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite multiple prior CDI treatments with the antibiotic standards of care, vancomycin (VAN) and/or fidaxomicin (FDX) Following acute treatment with ibezapolstat (IBZ), these beneficial...

Acurx Pharmaceuticals (NASDAQ: ACXP) reported new microbiome and in vitro data on its antibiotic ibezapolstat in multiply‑recurrent Clostridioides difficile infection (rCDI), presented at the 18th Biennial Congress of the Anaerobe Society of the Americas.According to Acurx and University of Houston researchers, beneficial gut bacteria involved in bile acid metabolism persist in patients with ≥2 CDI recurrences despite multiple prior vancomycin and/or fidaxomicin courses, and may regrow after ibezapolstat, which showed microbiome selectivity in earlier trials. Laboratory studies indicated ibezapolstat effectively killed C. difficile in planktonic and biofilm co‑culture with Enterococcus, outperforming fidaxomicin in biofilm killing and avoiding vancomycin‑associated VRE overgrowth. Acurx has initiated start‑up activities for a 20‑patient open‑label rCDI pilot trial and plans an active‑controlled Phase 3 rCDI registration trial, alongside an international Phase 3 program in acute CDI, supported by consistent FDA and EMA feedback and existing FDA QIDP/Fast Track and EMA SME designations.

Acurx Pharmaceuticals has showcased promising results from its DNA pol IIIC inhibitors at the LED3 Conference, demonstrating advances in antimicrobial treatments.

Acurx Pharmaceuticals reveals strong financial results and groundbreaking advancements in antibiotic development for difficult infections during Q1 2026.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q1 2026 results and business updates. Cash was $9.3M vs. $7.6M at year-end 2025, after raising about $3.1M via its equity line. Net loss narrowed to $1.7M ($0.62/share) from $2.1M.The company advanced ibezapolstat for C. difficile, initiating a Phase 2 rCDI trial and preparing Phase 3 acute CDI studies, while expanding its global DNA pol IIIC patent estate with new U.S. and Korean grants.

Acurx Pharmaceuticals provides a comprehensive update on their financial performance for 2025, including innovative trials, strategic advancements in antibiotic development, and significant operational achievements.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported full-year 2025 results and a business update on March 13, 2026. Key items: cash $7.6M, gross equity-line proceeds ~$4.0M in 2025, net loss $8.0M for 2025, and 2,348,113 shares outstanding.Clinical highlights include a planned open-label 20-patient rCDI pilot, Phase 2 ibezapolstat results (96% clinical cure of 26 patients, no recurrence), a new USPTO patent to Dec 2039, and structural biology publication supporting the Pol IIIC inhibitor program.